| 영문 | receptor | 한글 | 수용체 |
|---|---|---|---|
| 설명 | 세포질내 또는 세포표면에 존재하는 분자구조로서 특이물질과 선택적으로 결합하며 결합에 의해 특이한 생리적 작용을 나타낸다. 펩티드호르몬, 신경전달물질, 항원, 보체, 면역글로불린에 대한 세포표면 수용체와 스테로이드에 대한 세포질내 수용체가 있다. |
||
| BZRP | benzodiazepine receptor peripheral [type] |
|---|---|
| BDP | beclomethasone dipropionate; benzodiazepine; bilateral diaphragmatic paralysis; bronchopulmonary dys... |
| BZ | benzodiazepine |
| BZD | benzodiazepine |
| ER | efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re... |
| DA | Dopamine agonists |
|---|---|
| GnRHa | Gonadotrophin releasing hormone agonists |
| BDZR | Benzodiazepine receptor |
| BZR | Benzodiazepine receptor |
| PBzR | Peripheral benzodiazepine receptor |
| benzodiazepine | <pharmacology> A class of drug widely used in medical practice as CNS depressants, for example diazepam (the tranquilliser Valium). Enhance the inhibitory action of GABA by modulating GABAA receptors. (06 Aug 1998) |
|---|---|
| adrenergic agonists | Drugs that bind to and activate adrenergic receptors. (12 Dec 1998) |
| adrenergic alpha-agonists | Drugs that selectively bind to and activate alpha adrenergic receptors. (12 Dec 1998) |
| adrenergic beta-agonists | Drugs that selectively bind to and activate beta-adrenergic receptors. (12 Dec 1998) |
| gaba agonists | Drugs that bind to and activate gaba receptors (receptors, gaba). (12 Dec 1998) |
| cholinergic agonists | Drugs that bind to and activate cholinergic receptors. (12 Dec 1998) |
| myeloablative agonists | Agents that destroy bone marrow activity. They are used to prepare patients for bone marrow or stem cell transplantation. (12 Dec 1998) |
| serotonin agonists | Agents that have an affinity for serotonin receptors and are able to mimic the effects of serotonin by stimulating the physiologic activity at the cell receptors. These compounds are used as antidepressants, anxiolytics, and in the treatment of migraine. (12 Dec 1998) |
| nicotinic agonists | Drugs that bind to and activate nicotinic cholinergic receptors (receptors, nicotinic). Nicotinic agonists act at postganglionic nicotinic receptors, at neuroeffector junctions in the peripheral nervous system, and at nicotinic receptors in the central nervous system. Agents that function as neuromuscular depolarising blocking agents are included here because they activate nicotinic receptors, although they are used clinically to block nicotinic transmission. (12 Dec 1998) |
| dopamine agonists | Drugs that bind to and activate dopamine receptors. (12 Dec 1998) |
| excitatory amino acid agonists | Drugs that bind to and activate excitatory amino acid receptors. (12 Dec 1998) |
| lhrh agonists | Compounds that are similar to LHRH (luteinizing hormone-releasing hormone). (12 Dec 1998) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
| AMPA receptor | <cell biology> Glutamate operated ion channel. See: excitatory amino acid receptor channels. (05 Feb 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|